Figure S2 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3

Ling Ding,Xi Chen,Xiaqing Xu,Yuli Qian,Guikai Liang,Fengqi Yao,Zhangting Yao,Honghai Wu,Jieqiong Zhang,Qiaojun He,Bo Yang

DOI: https://doi.org/10.1158/2326-6066.22536380

2023-01-01

Abstract:PARP inhibitors upregulate the protein level of PD-L1.

What problem does this paper attempt to address?

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Tao Zhu,Ju-Yan Zheng,Ling-Ling Huang,Yan-Hong Wang,Di-Fei Yao,Hai-Bin Dai

DOI: https://doi.org/10.3389/fphar.2023.1137151

IF: 5.6

2023-01-01

Frontiers in Pharmacology

Abstract:Poly (ADP-ribose) polymerase 1 (PARP1) is a key DNA damage sensor that is recruited to damaged sites after DNA strand breaks to initiate DNA repair. This is achieved by catalyzing attachment of ADP-ribose moieties, which are donated from NAD+, on the amino acid residues of itself or other acceptor proteins. PARP inhibitors (PARPi) that inhibit PARP catalytic activity and induce PARP trapping are commonly used for treating BRCA1/2-deficient breast and ovarian cancers through synergistic lethality. Unfortunately, resistance to PARPi frequently occurs. In this review, we present the novel substrates and regulators of the PARP1-catalyzed poly (ADP-ribosyl)ation (PARylatison) that have been identified in the last 3 years. The overall aim is the presentation of protein interactions of potential therapeutic intervention for overcoming the resistance to PARPi.
PARP1 Inhibitors Attenuate AKT Phosphorylation Via the Upregulation of PHLPP1

Shuai Wang,Huibo Wang,Ben C. Davis,Jiyong Liang,Rutao Cui,Sai-Juan Chen,Zhi-Xiang Xu

DOI: https://doi.org/10.1016/j.bbrc.2011.07.107

IF: 3.1

2011-01-01

Biochemical and Biophysical Research Communications

Abstract:Poly(ADP-ribose) polymerase-1 (PARP1) inhibitors are emerging as an important class of drugs for treating BRCA-deficient cancers. Recent discoveries have shown that PARP1 inhibitors may treat other cancer patients in addition to the relatively small proportion of patients carrying BRCA mutations. However, the additional targets by which PARP1 inhibitor-mediated tumor suppression remain poorly understood. In this study, we show that two PARP1 inhibitors, PJ-34 and 3-AB, attenuate AKT phosphorylation at serine 473 (S473) independent of DNA repair impairment. These inhibitors decrease the AKT-associated phosphorylation of FOXO3A, enhance the nuclear retention of FOXO3A, and activate its transcriptional activity. We further demonstrate that treatment with PJ-34 or 3-AB dramatically increases the level of PHLPP1. Overexpression of PHLPP1 enhances the PARP1 inhibitor-induced downregulation of AKT phosphorylation and increases tumor cell death. In contrast, knockdown of PHLPP1 abrogates the PARP1 inhibitor-mediated AKT inhibition and desensitizes cells to its treatment. Therefore, our findings not only show the robust role of PARP1 inhibitors in AKT inhibition but also develop a novel strategy to increase the effectiveness of cancer treatment via PARP1 inhibitor-induced PHLPP1 upregulation.
Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells.

Xuerui Luo,Jia Nie,Shuaiwei Wang,Zuojia Chen,WanJun Chen,Dan Li,Hui Hu,Bin Li

DOI: https://doi.org/10.1074/jbc.m115.661611

IF: 5.485

2015-01-01

Journal of Biological Chemistry

Abstract:Poly(ADP-ribose) polymerase 1 (PARP-1) is an ADP-ribosylating enzyme participating in diverse cellular functions. The roles of PARP-1 in the immune system, however, have not been well understood. Here we find that PARP-1 interacts with FOXP3 and induces its poly(ADP-ribosyl)ation. By using PARP-1 inhibitors, we show that reduced poly(ADP-ribosyl)ation of FOXP3 results in not only FOXP3 stabilization and increased FOXP3 downstream genes but also enhanced suppressive function of regulatory T cells. Our results suggest that PARP-1 negatively regulates the suppressive function of Treg cells at the posttranslational level via FOXP3 poly(ADP-ribosyl)ation. This finding has implications for developing PARP-1 inhibitors as potential agents for the prevention and treatment of autoimmune diseases.
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Heng-Huan Lee,M. Hung,Jung-Mao Hsu,Yi Du,J. Litton,W. Xia,H. Yamaguchi,J. Hsu,Mei-Kuang Chen,Shiping Jiao,Wen-Hsuan Yu,Seung-Oe Lim,Shih-Shin Chang,B. Arun,G. Hortobagyi,C. Chou,Chia‐Wei Li,Yongkun Wei

DOI: https://doi.org/10.1158/1078-0432.CCR-16-3215

IF: 13.801

2017-02-06

Clinical Cancer Research

Abstract:Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates PARP inhibitor (PARPi) in tumor suppression. Experimental Design: Breast cancer cell lines, xenograft tumors, and syngeneic tumors treated with PARPi were assessed for PD-L1 expression by immunoblotting, IHC, and FACS analyses. The phospho-kinase antibody array screen was used to explore the underlying mechanism of PARPi-induced PD-L1 upregulation. The therapeutic efficacy of PARPi alone, PD-L1 blockade alone, or their combination was tested in a syngeneic tumor model. The tumor-infiltrating lymphocytes and tumor cells isolated from syngeneic tumors were analyzed by CyTOF and FACS to evaluate the activity of antitumor immunity in the tumor microenvironment. Results: PARPi upregulated PD-L1 expression in breast cancer cell lines and animal models. Mechanistically, PARPi inactivated GSK3β, which in turn enhanced PARPi-mediated PD-L1 upregulation. PARPi attenuated anticancer immunity via upregulation of PD-L1, and blockade of PD-L1 resensitized PARPi-treated cancer cells to T-cell killing. The combination of PARPi and anti-PD-L1 therapy compared with each agent alone significantly increased the therapeutic efficacy in vivo. Conclusions: Our study demonstrates a cross-talk between PARPi and tumor-associated immunosuppression and provides evidence to support the combination of PARPi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer. Clin Cancer Res; 23(14); 3711–20. ©2017 AACR.

Biology,Medicine
Inhibition of PARP1 Increases IRF-dependent Gene Transcription in Jurkat Cells.

Cheng Wang,Meng Du,Dan Huang,Kun Huang,Kai Huang

DOI: https://doi.org/10.1007/s11596-019-2043-1

2019-01-01

Current Medical Science

Abstract:Poly(ADP-ribose) polymerase 1 (PARP1) plays important roles in the regulation of transcription factors. Mounting evidence has shown that inhibition of PARP1 influences the expression of genes associated with inflammatory response. Interferon regulatory factor 1 (IRF1) is a critical transcription factor for the development of both the innate and adaptive immune responses against infections. However, the molecular mechanism through which PARP1 mediates the effects has not been clearly demonstrated. Jurkat cells were exposed to dexamethasone (Dex) or PARP1 inhibitor PJ34. The expression levels of IL-12, LMP2, OAS1 and PKR were detected using real-time RT-PCR. The interactions between PARP1 and IRF1 were examined by co-immunoprecipitation (co-IP) assays. We further explored the mechanism of PARP1 suppressing IRF1 by assessing the activities of interferon stimulated response element (ISRE). The mRNA expression of IL-12, LMP2, OAS1 and PKR was obviously suppressed by Dex in Jurkat cells, which could be rescued by PJ34 treatment. Luciferase study revealed that poly(ADP-ribosyl)- ation suppressed IRF1-mediated transcription through preventing the binding of IRF1 to ISREs. PARP1 inhibited IRF1-mediated transcription in Jurkat cells by preventing IRF1 binding to ISREs in the promoters of target genes. It is suggested that PARP1 is a crucial regulator of IRF1-mediated immune response. This study provides experimental evidence for the possible application of PARP1 inhibitors in the treatment of IRF1-related immune anergy.
Figure 3 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition

Hanwei Zhang,Ann Ly,Emily Chou,Liang Wang,Paul Zhang,Kris Prado,Yiqian Gu,Matteo Pellegrini,Arnold I. Chin

DOI: https://doi.org/10.1158/2767-9764.26830505

2024-01-01

Abstract:FOXP3 influences immune resistance and differentiation in the genetically defined PARCB2 bladder cancer model. A, Generation of clonal PARCB1/2 FOXP3Δ3 and PARCB1/2 FOXP3 lines through lentiviral infection of PARCB1 and PARCB2 cells. B, Expression of FOXP3Δ3, FOXP3, and PD-L1 in PARCB1/2, PARCB1/2 FOXP3Δ3, and PARCB1/2 FOXP3 representative clonal lines by qPCR. The mean and SD of two independent experiments, P values indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. C, Expression of FOXP3 and PD-L1 in PARCB2, PARCB2 FOXP3Δ3, and PARCB2 FOXP3 clonal lines by Western blotting. Sizes in kD as indicated. Full Western blots are shown in Supplementary Fig. S1. D, Growth of PARCB2, PARCB2 FOXP3Δ3, and PARCB2 FOXP3 cells in NSG mice. The mean and SEM of three animals per group. E, Histology and immunofluorescence of FOXP3 and PD-L1 in PARCB2, PARCB2 FOXP3Δ3, and PARCB2 FOXP3 tumors from NSG mice. Representative of three independent tumors. Exposure times listed in Supplementary Table S6. F, IHC of chromogranin A and NSE in PARCB2, PARCB2 FOXP3Δ3, and PARCB2 FOXP3 tumors from NSG mice. Representative of three independent tumors. G, Immunofluorescence of E-cadherin, N-cadherin, and ICAM-1 in PARCB2, PARCB2 FOXP3Δ3, and PARCB2 FOXP3 tumors from NSG mice. Representative of three independent tumors. Bar graphs represent the mean of 10 representative sections from three independent tumors. The mean and SD as shown, P values indicated. Exposure times listed in Supplementary Table S6.
PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Yali Wang,Kun Zheng,Hua Xiong,Yongbiao Huang,Xiuqiong Chen,Yilu Zhou,Wan Qin,Jinfang Su,Rui Chen,Hong Qiu,Xianglin Yuan,Yihua Wang,Yanmei Zou

DOI: https://doi.org/10.3389/fimmu.2021.762989

IF: 7.3

2021-12-17

Frontiers in Immunology

Abstract:Despite recent improvements in treatment modalities, pancreatic cancer remains a highly lethal tumor with mortality rate increasing every year. Poly (ADP-ribose) polymerase (PARP) inhibitors are now used in pancreatic cancer as a breakthrough in targeted therapy. This study focused on whether PARP inhibitors (PARPis) can affect programmed death ligand-1 (PD-L1) expression in pancreatic cancer and whether immune checkpoint inhibitors of PD-L1/programmed death 1 (PD-1) can enhance the anti-tumor effects of PARPis. Here we found that PARPi, pamiparib, up-regulated PD-L1 expression on the surface of pancreatic cancer cells in vitro and in vivo . Mechanistically, pamiparib induced PD-L1 expression via JAK2/STAT3 pathway, at least partially, in pancreatic cancer. Importantly, pamiparib attenuated tumor growth; while co-administration of pamiparib with PD-L1 blockers significantly improved the therapeutic efficacy in vivo compared with monotherapy. Combination therapy resulted in an altered tumor immune microenvironment with a significant increase in windiness of CD8 + T cells, suggesting a potential role of CD8 + T cells in the combination therapy. Together, this study provides evidence for the clinical application of PARPis with anti-PD-L1/PD-1 drugs in the treatment of pancreatic cancer.

immunology
Data from ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers

Ding Xiao,Ting Zeng,Wei Zhu,Zheng-Zheng Yu,Wei Huang,Hong Yi,Shan-Shan Lu,Juan Feng,Xue-Ping Feng,Di Wu,Qi Wen,Jian-Hua Zhou,Li Yuan,Wei Zhuang,Zhi-Qiang Xiao

DOI: https://doi.org/10.1158/2326-6066.c.6864866

2023-01-01

Abstract:AbstractThe deregulation of Annexin A1 (ANXA1), a regulator of inflammation and immunity, leads to cancer growth and metastasis. However, whether ANXA1 is involved in cancer immunosuppression is still unclear. Here, we report that ANXA1 knockdown (i) dramatically downregulates programmed cell death-ligand 1 (PD-L1) expression in breast cancer, lung cancer, and melanoma cells; (ii) promotes T cell–mediated killing of cancer cells in vitro; and (iii) inhibits cancer immune escape in immune-competent mice via downregulating PD-L1 expression and increasing the number and killing activity of CD8+ T cells. Mechanistically, ANXA1 functioned as a sponge molecule for interaction of PARP1 and Stat3. Specifically, binding of ANXA1 to PARP1 decreased PARP1’s binding to Stat3, which reduced poly(ADP-ribosyl)ation and dephosphorylation of Stat3 and thus, increased Stat3’s transcriptional activity, leading to transcriptionally upregulated expression of PD-L1 in multiple cancer cells. In clinical samples, expression of ANXA1 and PD-L1 was significantly higher in breast cancer, non–small cell lung cancer, and skin cutaneous melanoma compared with corresponding normal tissues and positively correlated in cancer tissues. Moreover, using both ANXA1 and PD-L1 proteins for predicting efficacy of anti–PD-1 immunotherapy and patient prognosis was superior to using individual proteins. Our data suggest that ANXA1 promotes cancer immune escape via binding PARP1 and upregulating Stat3-induced expression of PD-L1, that ANXA1 is a potential new target for cancer immunotherapy, and combination of ANXA1 and PD-L1 expression is a potential marker for predicting efficacy of anti–PD-1 immunotherapy in multiple cancers.
EZH2 directly methylates PARP1 and regulates its activity in cancer

Qingshu Meng,Jiangchuan Shen,Yanan Ren,Qi Liu,Rui Wang,Qiaqia Li,Weihua Jiang,Quan Wang,Yixiang Zhang,Jonathan C. Trinidad,Xiaotong Lu,Tingyou Wang,Yanqiang Li,Chaehyun Yum,Yang Yi,Yongyong Yang,Dongyu Zhao,Clair Harris,Sundeep Kalantry,Kaifu Chen,Rendong Yang,Hengyao Niu,Qi Cao

DOI: https://doi.org/10.1126/sciadv.adl2804

IF: 13.6

2024-11-28

Science Advances

Abstract:DNA repair dysregulation is a key driver of cancer development. Understanding the molecular mechanisms underlying DNA repair dysregulation in cancer cells is crucial for cancer development and therapies. Here, we report that enhancer of zeste homolog 2 (EZH2) directly methylates poly(adenosine diphosphate–ribose) polymerase-1 (PARP-1), an essential enzyme involved in DNA repair, and regulates its activity. Functionally, EZH2-catalyzed methylation represses PARP1 catalytic activity, down-regulates the recruitment of x-ray repair cross-complementing group-1 to DNA lesions and its associated DNA damage repair; on the other hand, it protects the cells from nicotinamide adenine dinucleotide overconsumption upon DNA damage formation. Meanwhile, EZH2-mediated methylation regulates PARP1 transcriptional and oncogenic activity, at least in part, through impairing PARP1-E2F1 interaction and E2F1 transcription factor activity. EZH2 and PARP1 inhibitors synergistically suppress prostate cancer growth. Collectively, our findings uncover an insight of EZH2 functions in fine-tuning PARP1 activity during DNA damage repair and cancer progression, which provides a rationale for combinational targeting EZH2 and PARP1 in cancer.

multidisciplinary sciences
Targeting PARP1 modulates METTL3 promoter chromatin accessibility and associated LPAR5 RNA m6A methylation to enhance cancer cell radiosensitivity

Xiaoya Sun,Chenjun Bai,Haozheng Li,Dafei Xie,Shi Chen,Yang Han,Jinhua Luo,Yang Li,Yumeng Ye,Jin Jia,Xin Huang,Hua Guan,Dingxin Long,Ruixue Huang,Shanshan Gao,Ping-Kun Zhou,Xiao-Ya Sun,Chen-Jun Bai,Shan-shan Gao

DOI: https://doi.org/10.1016/j.ymthe.2023.07.018

IF: 12.91

2023-07-01

Molecular Therapy

Abstract:Chromatin remodeling and N6-methyladenosine (m6A) modification are two critical layers in controlling gene expression and DNA damage signaling in most eukaryotic bioprocesses. Here, we report that poly(ADP-ribose) polymerase 1 (PARP1) controls the chromatin accessibility of METTL3 to regulate its transcription and subsequent m6A methylation of poly(A)+ RNA in response to DNA damage induced by radiation. The transcription factors nuclear factor I-C (NFIC) and TATA binding protein (TBP) are dependent on PARP1 to access the METTL3 promoter to activate METTL3 transcription. Upon irradiation or PARP1 inhibitor treatment, PARP1 disassociated from METTL3 promoter chromatin, which resulted in attenuated accessibility of NFIC and TBP and, consequently, suppressed METTL3 expression and RNA m6A methylation. Lysophosphatidic Acid Receptor 5 (LPAR5) mRNA was identified as a target of METTL3, and m6A methylation was located at A1881. The level of m6A methylation of LPAR5 significantly decreased, along with METTL3 depression, in cells after irradiation or PARP1 inhibition. Mutation of the LPAR5 A1881 locus in its 3' UTR results in loss of m6A methylation and, consequently, decreased stability of LPAR5 mRNA. METTL3-targeted small-molecule inhibitors depress murine xenograft tumor growth and exhibit a synergistic effect with radiotherapy in vivo. These findings advance our comprehensive understanding of PARP-related biological roles, which may have implications for developing valuable therapeutic strategies for PARP1 inhibitors in oncology.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Figure S4 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418979

2023-01-01

Abstract:PD-L1 Attenuates Anti-tumor effect of RORC in Bladder cancer
PARP1 interacts with WDR5 to enhance target gene recognition and facilitate tumorigenesis

Yali Qin,Xiaochuan Dong,Manman Lu,Lingyun Jing,Qingchuan Chen,Fei Guan,Zhengkai Xiang,Jiaojuan Huang,Chengxuan Yang,Ximiao He,Jing Qu,Zhenhua Yang

DOI: https://doi.org/10.1016/j.canlet.2024.216952

IF: 9.756

2024-05-14

Cancer Letters

Abstract:Poly (ADP-ribose) polymerase-1 (PARP1) is a nuclear protein that attaches negatively charged poly (ADP-ribose) (PAR) to itself and other target proteins. While its function in DNA damage repair is well established, its role in target chromatin recognition and regulation of gene expression remains to be better understood. This study showed that PARP1 interacts with SET1/MLL complexes by binding directly to WDR5. Notably, although PARP1 does not modulate WDR5 PARylation or the global level of H3K4 methylation, it exerts locus-specific effects on WDR5 binding and H3K4 methylation. Interestingly, PARP1 and WDR5 show extensive co-localization on chromatin, with WDR5 facilitating the recognition and expression of target genes regulated by PARP1. Furthermore, we demonstrated that inhibition of the WDR5 Win site impedes the interaction between PARP1 and WDR5, thereby inhibiting PARP1 from binding to target genes. Finally, the combined inhibition of the WDR5 Win site and PARP shows a profound inhibitory effect on the proliferation of cancer cells. These findings illuminate intricate mechanisms underlying chromatin recognition, gene transcription, and tumorigenesis, shedding light on previously unrecognized roles of PARP1 and WDR5 in these processes.

oncology
PARP1 controls the transcription of CD24 by ADP-ribosylating the RNA helicase DDX5 in pancreatic cancer

Kang Chen,Manxiong Dai,Quanneng Luo,Yi Wang,Weitao Shen,Yan Liao,Yiying Zhou,Wei Cheng

DOI: https://doi.org/10.1016/j.biocel.2022.106358

2022-12-29

Abstract:The PARP1 protein plays a key role in DNA damage repair and ADP-ribosylation to regulate gene expression. Strategies to target PARP1 have rapidly been developed for cancer treatment. However, the role of the innate immune response in targeted anti-PARP1 therapy remains poorly understood. In this work, we aimed to elucidate the regulatory mechanism underlying the immunogenicity of PARP1 and explore efficient therapeutic strategies to enhance the antitumor effect of PARP inhibitors. The relationships between PARP1 expression and immunosuppressive factors were examined by qRTPCR and immunoblot analysis. DNA pull-down, chromatin immunoprecipitation–quantitative PCR (ChIPqPCR) and luciferase reporter assays were employed to reveal the mechanism by which the expression of the immune checkpoint regulator CD24 is regulated by PARP1. Phagocytosis assays and pancreatic cancer animal models were applied to evaluate the therapeutic effect of simultaneous disruption of PARP1 and the antiphagocytic factor CD24. Upregulation of the innate immunosuppressive factor CD24 was observed in pancreatic cancer during PARP1 inhibition. The activating effect of targeting CD24 on macrophage phagocytosis was verified. Then, we showed that PARP1 attenuated the transcription of CD24 by ADP-ribosylating the transcription factor DDX5 in pancreatic cancer. Combined blockade of PARP1 and the antiphagocytic factor CD24 elicited a synergetic antitumor effect in pancreatic cancer. Our research provided evidence that combination treatment with PARP inhibitors and CD24 blocking monoclonal antibodies (mAbs) could be an effective strategy to improve the clinical therapeutic response in pancreatic cancer.

cell biology,biochemistry & molecular biology
PARP-1 Controls Immunosuppressive Function of Regulatory T Cells by Destabilizing Foxp3

Pin Zhang,Takashi Maruyama,Joanne E. Konkel,Brittany Abbatiello,Brian Zamarron,Zhao-qi Wang,WanJun Chen

DOI: https://doi.org/10.1371/journal.pone.0071590

IF: 3.7

2013-01-01

PLoS ONE

Abstract:Poly (ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme and transcription factor that is involved in inflammatory response, but its role in T cell response remains largely unknown. We show here that PARP-1 regulates the suppressive function of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs). Specifically, Tregs in mice with a null mutation of the PARP-1 gene (PARP-1(-/-)) showed significantly stronger suppressive activity than did wild-type Tregs in culture. We elucidate that this enhanced suppressive function is attributed to sustained higher expression of Foxp3 and CD25 in PARP-1(-/-) Tregs. Furthermore, in PARP-1(-/-) Tregs, Foxp3 protein shows substantially higher levels of binding to the conserved non-coding DNA sequence 2 (CNS2) at the foxp3 gene, a region important in maintaining Foxp3 gene expression in Tregs. Thus, our data reveal a role for PARP-1 in controlling the function of Tregs through modulation of the stable expression of Foxp3.
ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating Stat3-induced expression of PD-L1 in multiple cancers

Ding Xiao,Ting Zeng,Wei Zhu,Zheng-Zheng Yu,Wei Huang,Hong Yi,Shan-Shan Lu,Juan Feng,Xue-Ping Feng,Di Wu,Qi Wen,Jian-Hua Zhou,Li Yuan,Wei Zhuang,Zhi-Qiang Xiao

DOI: https://doi.org/10.1158/2326-6066.cir-22-0896

IF: 10.1

2023-08-13

Cancer Immunology Research

Abstract:The deregulation of annexin A1 (ANXA1), a regulator of inflammation and immunity, leads to cancer growth and metastasis. However, whether ANXA1 is involved in cancer immunosuppression is still unclear. Here, we report that ANXA1 knockdown (i) dramatically downregulates programmed cell death-ligand 1 (PD-L1) expression in breast cancer, lung cancer, and melanoma cells; (ii) promotes T cell-mediated killing of cancer cells in vitro; and (iii) inhibits cancer immune escape in immune-competent mice via downregulating PD-L1 expression and increasing the number and killing activity of CD8+ T cells. Mechanistically, ANXA1 functioned as a sponge molecule for interaction of PARP1 and Stat3. Specifically, binding of ANXA1 to PARP1 decreased PARP1's binding to Stat3, which reduced poly(ADP-ribosyl)ation and dephosphorylation of Stat3 and thus, increased Stat3's transcriptional activity, leading to transcriptionally upregulated expression of PD-L1 in multiple cancer cells. In clinical samples, expression of ANXA1 and PD-L1 was significantly higher in breast cancer, non-small cell lung cancer, and skin cutaneous melanoma compared to corresponding normal tissues and positively correlated in cancer tissues. Moreover, using both ANXA1 and PD-L1 proteins for predicting efficacy of anti-PD-1 immunotherapy and patient prognosis were superior to using individual proteins. Our data suggest that ANXA1 promotes cancer immune escape via binding PARP1 and upregulating Stat3-induced expression of PD-L1, that ANXA1 is a potential new target for cancer immunotherapy, and combination of ANXA1 and PD-L1 expression is a potential marker for predicting efficacy of anti-PD-1 immunotherapy in multiple cancers.

oncology,immunology
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

Ge Qin,Xin Wang,Shubiao Ye,Yizhuo Li,Miao Chen,Shusen Wang,Tao Qin,Changlin Zhang,Yixin Li,Qian Long,Huabin Hu,Dingbo Shi,Jiaping Li,Kai Zhang,Qinglian Zhai,Yanlai Tang,Tiebang Kang,Ping Lan,Fangyun Xie,Jianjun Lu,Wuguo Deng

DOI: https://doi.org/10.1038/s41467-020-15364-z

IF: 16.6

2020-04-03

Nature Communications

Abstract:Abstract Programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) interaction plays a crucial role in tumor-associated immune escape. Here, we verify that triple-negative breast cancer (TNBC) has higher PD-L1 expression than other subtypes. We then discover that nucleophosmin (NPM1) binds to PD-L1 promoter specifically in TNBC cells and activates PD-L1 transcription, thus inhibiting T cell activity in vitro and in vivo. Furthermore, we demonstrate that PARP1 suppresses PD-L1 transcription through its interaction with the nucleic acid binding domain of NPM1, which is required for the binding of NPM1 at PD-L1 promoter. Consistently, the PARP1 inhibitor olaparib elevates PD-L1 expression in TNBC and exerts a better effect with anti-PD-L1 therapy. Together, our research has revealed NPM1 as a transcription regulator of PD-L1 in TNBC, which could lead to potential therapeutic strategies to enhance the efficacy of cancer immunotherapy.

multidisciplinary sciences
Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.

Kaishun Hu,Wenjing Wu,Yu Li,Lehang Lin,Dong Chen,Haiyan Yan,Xing Xiao,Hengxing Chen,Zhen Chen,Yin Zhang,Shuangbing Xu,Yabin Guo,H Phillip Koeffler,Erwei Song,Dong Yin

DOI: https://doi.org/10.15252/embr.201846166

IF: 9.071

2019-01-01

EMBO Reports

Abstract:The bromodomain-containing protein 7 (BRD7) is a tumour suppressor protein with critical roles in cell cycle transition and transcriptional regulation. Whether BRD7 is regulated by post-translational modifications remains poorly understood. Here, we find that chemotherapy-induced DNA damage leads to the rapid degradation of BRD7 in various cancer cell lines. PARP-1 binds and poly(ADP)ribosylates BRD7, which enhances its ubiquitination and degradation through the PAR-binding E3 ubiquitin ligase RNF146. Moreover, the PARP1 inhibitor Olaparib significantly enhances the sensitivity of BRD7-positive cancer cells to chemotherapeutic drugs, while it has little effect on cells with low BRD7 expression. Taken together, our findings show that PARP1 induces the degradation of BRD7 resulting in cancer cell resistance to DNA-damaging agents. BRD7 might thus serve as potential biomarker in clinical trial for the prediction of synergistic effects between chemotherapeutic drugs and PARP inhibitors.
IMMUNOBIOLOGY PARP-1 regulates expression of TGF-b receptors in T cells

Pin Zhang,Hiroko Nakatsukasa,Eric Tu,Shimpei Kasagi,Kairong Cui,Masaki Ishikawa,Joanne E. Konkel,Takashi Maruyama,Gang Wei,Brittany Abbatiello,Zhao-Qi Wang,Keji Zhao,WanJun Chen

2013-01-01

Abstract:Transforming growth factor-b (TGF-b) receptor I (TbRI) and II (TbRII) are essential components of TGF-b signalingand play an indispensable role in generation of regulatory T cells (Tregs). In mice, selective deletion of TbRIor TbRII in T cells results in a severe defect in Treg generation. However, the underlying mechanisms are poorly understood. The expression of TbRs in T cells determines TGF-b signal strength, which has profound effects on T-cell responses and differentiation. Thus, insights into the mechanisms that regulate TbR expression are not only essential for understanding Treg generation, but also important for treatment of autoimmune diseases, transplant rejection, cancer, and infection. Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that is conventionally linked to DNA repair. However, PARP-1 has also been shown to function as a transcription factor involved in the transcription of many genes. Inhibition of PARP-1 activity by inhibitors or gene mutation has been shown to lead to both suppression and exacerbation of chronic inflammation and autoimmune disease models. Recently, it was shown that deletion of PARP-1 inhibited nuclear factor–kB (NF-kB) activation and decreased tumor necrosis factor-a (TNF-a) and inducible nitric oxide synthesis in macrophages. However, the role of PARP-1 in T-cell–mediated immune responses remains elusive. Here, we show that PARP-1 regulates the expression of TbRs and thereby controls Treg generation in T cells. Deletion of PARP-1 in mice (PARP-1) results in a T-cell–intrinsic preference to generate more thymic Tregs and convert more naive T cells into induced Tregs in vitro and in vivo. Treg increase was attributed to enhanced sensitivity of CD4 T cells to TGF-b signals by upregulation of both TbRI and II, and subsequent Smad2/3 activation in PARP-1 T cells. We show that PARP-1 inhibits TbRI expression through its enzymatic function, and modulates TbRII by directly binding to TbRII gene (Tgfbr2). In addition, PARP-1 deficiency enriched the binding of Smad3 at the enhancer of the forkhead box p3 (Foxp3) gene. Importantly, inhibition of PARP-1 enzyme activity resulted in increased FOXP3 and TGFBR genes expression in human CD4 T cells. Together, these data reveal an unrecognized role for PARP1 in the regulation of TbR expression.
Figure S9 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors

Sailing Shi,Shengqing Gu,Tong Han,Wubing Zhang,Lei Huang,Ziyi Li,Deng Pan,Jingxin Fu,Jun Ge,Myles Brown,Peng Zhang,Peng Jiang,Kai W. Wucherpfennig,X. Shirley Liu

DOI: https://doi.org/10.1158/1078-0432.22476150.v1

2023-01-01

Abstract:Sup.Fig.9: The effect of Man2a1 inhibition on the immune cell infiltration.
Figure S6 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Qi Zhou,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yan Zhu,Yi Shen,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418973.v1

2023-01-01

Abstract:The associations among the expression of PD-L1, ITGB6, STAT3 and p-STAT3 and survival of Bladder Urothelial Cancer Patients

Figure S2 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

PARP1 Inhibitors Attenuate AKT Phosphorylation Via the Upregulation of PHLPP1

Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells.

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Inhibition of PARP1 Increases IRF-dependent Gene Transcription in Jurkat Cells.

Figure 3 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Data from ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers

EZH2 directly methylates PARP1 and regulates its activity in cancer

Targeting PARP1 modulates METTL3 promoter chromatin accessibility and associated LPAR5 RNA m6A methylation to enhance cancer cell radiosensitivity

Figure S4 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

PARP1 interacts with WDR5 to enhance target gene recognition and facilitate tumorigenesis

PARP1 controls the transcription of CD24 by ADP-ribosylating the RNA helicase DDX5 in pancreatic cancer

PARP-1 Controls Immunosuppressive Function of Regulatory T Cells by Destabilizing Foxp3

ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating Stat3-induced expression of PD-L1 in multiple cancers

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.

IMMUNOBIOLOGY PARP-1 regulates expression of TGF-b receptors in T cells

Figure S9 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors

Figure S6 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer